Stock of the Day

Stoke Therapeutics (STOK)

$8.33

-$0.41 (-4.7%)

Market Cap: $462.93M

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Recent News

• Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (finance.yahoo.com)
• Stoke Therapeutics price target raised to $47 from $35 at H.C. Wainwright (markets.businessinsider.com)
• Biogen continues dealmaking buzz with Stoke Therapeutics (bizjournals.com)
• Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (finance.yahoo.com)
• Chardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK) (markets.businessinsider.com)
• Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration (marketwatch.com)
• Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally (msn.com)
• Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (globenewswire.com)
• Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer (seekingalpha.com)